Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2016-04-04

Clinical Trial Update: Linagliptin as Add on Therapy to Empagliflozin 10 mg or 25 mg With Background Metformin in Patient With Type 2 Diabetes [Phase 3]

View source ↗

Summary

Phase 3 trial results evaluating linagliptin added to empagliflozin with background metformin in adults with type 2 diabetes have been completed and results pos…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Empagliflozin (empagliflozin)
  • Linagliptin (linagliptin)
  • metformin (metformin)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Diabetes Mellitus, Type 2 | Phase 3 | Status: COMPLETED | Results posted: 2016-04-04